China Biotechs, CDMOs Embrace Uncertain Future, New Options Amid WuXi Woes
Executive Summary
The shockwave of WuXi's withdrawal from BIO is ripping through the Chinese contract services sector. While some remain hopeful, others are preparing Plan B.